Home > Insider Trading > Filing (0001209191-21-042811)

Filing Details

Accession Number:: 0001209191-21-042811
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-23 17:54:30
Reporting Period:: 2021-06-21

Accepted Time:: 2021-06-23 17:54:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	Biological Products, (No Disgnostic Substances) (2836)	473173478

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682017	Rodger Novak	C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139	President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Disposition	2021-06-21	1,171	$125.58	646,836	No	4	S	Direct
Common Shares	Disposition	2021-06-21	881	$126.62	645,955	No	4	S	Direct
Common Shares	Disposition	2021-06-21	2,969	$127.71	642,986	No	4	S	Direct
Common Shares	Disposition	2021-06-21	12,630	$128.76	630,356	No	4	S	Direct
Common Shares	Disposition	2021-06-21	7,299	$129.46	623,057	No	4	S	Direct
Common Shares	Disposition	2021-06-21	50	$130.27	623,007	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.095 to $126.08, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.175 to $127.175, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.19 to $128.19, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.195 to $129.195, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.20 to $130.11, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.